[Juvenile myelomonocytic leukemia and pediatric myelodysplastic syndromes]

Abstract

Juvenile myelomonocytic leukemia (JMML) and myelodysplastic syndromes (MDS) of children are rare and aggressive diseases. They both have the particularity of being very frequently associated with an underlying predisposition syndrome, which must be systematically investigated by meticulous clinical exam completed by molecular analysis on fibroblasts, in order to guarantee the best therapeutic management. New generation sequencing techniques have made it possible to better define the landscape of constitutional predisposing pathologies, to understand the clonal evolution that leads to the development of hematological malignancies and to identify new prognostic markers. In these two diseases, the only curative treatment is allogeneic hematopoietic stem cell transplantation, for which the appropriate timeframe, the type of donor and the conditioning must be decided in consultation with the expert teams in each entity.

Keywords: Children; Juvenile myelomonocytic leukemia; Leucémies myélo-monocytaires juvéniles; Myelodysplastic syndrome; Pediatric; Predisposition; Prédisposition aux leucémies; Pédiatrie; Syndromes myélodysplasiques de l’enfant.